Taros’ SVP Drug Discovery Dr. Torsten Hoffmann appointed to ZeCardio Therapeutic’s Scientific Advisory Board

Barcelona, Spain & Dortmund, Germany, July 2019 ++++

ZeCardio Therapeutics (ZeCardioTx), a Barcelona based pharma company focused on the discovery of cardiovascular drugs using the zebrafish model and an innovative, proprietary screening and analysis platform, ZeCardio®, selected Taros Chemicals’ SVP Drug Discovery, Dr. Torsten Hoffmann, to join the company’s Scientific Advisory Board.

ZeCardioTx’s Co-Founder and CEO, Dr. Davide D’Amico, said: “I am delighted that Torsten is joining ZeCardioTx’s Advisory Board. His senior management experience and expertise in pharmaceutical R&D, coupled with his experience in preclinical drug discovery will be an inspiration to our people and our way of working.

“It is my great pleasure to be joining Davide and his talented team and look forward to leveraging my experience in drug discovery and pharmaceutical R&D to help ZeCardioTx develop its game changing technology and unlock the company’s full potential”, said Dr. Torsten Hoffmann.

With more than 20 years of international R&D leadership experience, Torsten is an expert in the field of Drug Discovery. For the past 6 years, he has served as Chief Operating Officer and Chief Scientific Officer at Silence Therapeutics, as Chief Scientific Officer and Managing Director at Proteros biostructures, and prior to that as Chief Scientific Officer and Executive Vice President at Zealand Pharma. During this tenure and under his leadership, he has been instrumental in building and growing proprietary R&D portfolios with the most advanced assets now conducting clinical phase 3 trials. Among other appointments, Torsten serves as consultant and SAB member at Hesperos, BioSolveIT and Elsevier.

Torsten started his career at Roche where he spent 16 years in various roles with increasing responsibility including Site Head of Medicinal Chemistry in Basel, and Head of the Global Roche Postdoc Fellowship Program. Under his leadership, his group created 52 new chemical lead series and more than 25 NCEs entered clinical trials as potential Roche medicines. Moreover, he is the lead inventor of the anti-emetic medicine Netupitant, discovered at Roche and approved by the FDA as Akynzeo© in 2014.